Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$8.00
-4.9%
$7.10
$2.05
$8.72
$749.90M-0.461.02 million shs782,249 shs
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
$9.61
-1.1%
$8.30
$4.70
$10.49
$739.58M2.491.30 million shs819,084 shs
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
$11.74
+4.4%
$9.71
$5.67
$26.56
$186.05M0.01104,956 shs181,535 shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$4.52
+1.8%
$5.22
$4.16
$14.45
$616.79M1.181.07 million shs1.02 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
+1.33%+7.27%+3.57%+73.76%+294.84%
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
-2.51%-2.70%+20.45%+47.27%+46.06%
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
+6.13%+9.76%+6.03%+67.71%-34.29%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-2.84%+2.07%-16.23%-3.48%-47.14%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.5541 of 5 stars
4.52.00.00.02.72.50.6
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
2.609 of 5 stars
3.63.00.00.02.40.80.6
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
4.6641 of 5 stars
4.33.00.04.23.81.70.6
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
3.3799 of 5 stars
3.42.00.00.03.13.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.00
Buy$11.7546.88% Upside
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
3.22
Buy$24.71157.17% Upside
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
2.57
Moderate Buy$21.5783.74% Upside
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.88
Moderate Buy$30.25569.25% Upside

Current Analyst Ratings Breakdown

Latest RAPT, AMLX, MNMD, and VIR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/12/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetNeutral ➝ Neutral$8.00 ➝ $9.00
8/8/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$51.00 ➝ $38.00
8/4/2025
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$25.00
8/1/2025
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
7/30/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Neutral$14.00
7/22/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$31.00
7/11/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
7/11/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeModerate Buy$12.00
7/10/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$10.00
7/10/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$27.00
6/24/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold
(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$87.37M8.16N/AN/A$1.88 per share4.26
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
N/AN/AN/AN/A$2.44 per shareN/A
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
$1.53M126.91N/AN/A$9.94 per share1.18
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$74.21M8.46N/AN/A$6.82 per share0.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$301.74M-$2.50N/AN/AN/AN/A-82.48%-70.15%N/A
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
-$108.68M-$1.53N/AN/AN/AN/A-50.24%-39.41%N/A
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
-$129.87M-$14.17N/AN/AN/AN/A-67.92%-59.59%N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$521.96M-$4.00N/AN/AN/A-2,895.94%-50.22%-40.78%10/30/2025 (Estimated)

Latest RAPT, AMLX, MNMD, and VIR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.44-$0.46-$0.02-$0.46N/AN/A
8/7/2025Q2 2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
-$0.61-$0.65-$0.04-$0.65N/AN/A
8/6/2025Q2 2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.72-$0.80-$0.08-$0.80$2.38 million$1.21 million
7/31/2025Q2 2025
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
-$0.38-$0.50-$0.12-$0.50N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/AN/AN/AN/AN/A
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
N/AN/AN/AN/AN/A
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
N/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
8.72
8.72
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
0.22
4.98
4.98
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
N/A
13.25
21.11
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/A
7.01
7.01

Institutional Ownership

CompanyInstitutional Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
27.91%
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
99.09%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
65.32%

Insider Ownership

CompanyInsider Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
12.30%
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
2.45%
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
2.36%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
16.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
20089.17 million78.20 millionOptionable
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
4076.09 million74.22 millionOptionable
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
8016.54 million16.15 millionOptionable
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
580138.92 million116.69 millionOptionable

Recent News About These Companies

Leerink Partnrs Issues Optimistic Forecast for VIR Earnings
Leerink Partnrs Issues Optimistic Outlook for VIR Earnings
Vir (VIR) Q2 Revenue Drops 61%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$8.00 -0.41 (-4.88%)
Closing price 04:00 PM Eastern
Extended Trading
$8.11 +0.11 (+1.36%)
As of 06:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Mind Medicine (MindMed) stock logo

Mind Medicine (MindMed) NASDAQ:MNMD

$9.61 -0.11 (-1.13%)
Closing price 04:00 PM Eastern
Extended Trading
$9.61 +0.00 (+0.01%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Rapt Therapeutics stock logo

Rapt Therapeutics NASDAQ:RAPT

$11.74 +0.49 (+4.36%)
Closing price 04:00 PM Eastern
Extended Trading
$11.74 0.00 (0.00%)
As of 06:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Vir Biotechnology stock logo

Vir Biotechnology NASDAQ:VIR

$4.52 +0.08 (+1.80%)
Closing price 04:00 PM Eastern
Extended Trading
$4.50 -0.02 (-0.53%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.